Research Article
[Retracted] Antileukemic Effects of Anti-miR-146a, Anti-miR-155, Anti-miR-181a, and Prednisolone on Childhood Acute Lymphoblastic Leukemia
Table 3
Effects of anti-miR and prednisolone treatment on the viability of SUP-B15 and NCI-BL 2171 cells.
| Treatment group | Viability compared to control (%) | | SUP-B15 | NCI-BL 2171 | |
| Anti-miR-146a | 29.62 | 57.36 | | Anti-miR-146a & IC50 dose of prednisolone | 2.44 | 52.32 | | Anti-miR-155 | 55.00 | 52.09 | | Anti-miR-155 & IC50 dose of prednisolone | 13.75 | 43.30 | | Anti-miR-181a | 13.03 | 58.18 | | Anti-miR-181a & IC50 dose of prednisolone | 9.17 | 46.91 | | Anti-let-7e | 9.17 | 49.82 | | Anti-let-7e & IC50 dose of prednisolone | 3.14 | 49.52 | | Anti-miR-146a + anti-miR-155 + anti-miR-181a + anti-let-7e combination | 13.75 | 41.10 | | Anti-miR-146a + anti-miR-155 + anti-miR-181a + anti-let-7e combination & IC50 dose of prednisolone | 0.00 | 52.22 | | IC50 dose of prednisolone | 41.25 | 56.91 | |
|
|
Fisher’s exact test, <0.05, <0.001, and <0.0001. |